News

The partnership grants Daewoong access to Salipro’s expertise and platform specifically designed for stabilising challenging membrane proteins such as G protein-coupled receptors (GPCRs), ion channels, and transporters. The

MRT-8102 is a NEK7-directed molecular glue degrader being developed to treat inflammatory diseases driven by the NLRP3 inflammasome and IL-1β. Monte Rosa Therapeutics CEO Markus Warmuth said: “The

Under the agreement, Neowise will be eligible for an upfront payment and will also receive future milestone payments. These payments are contingent upon reaching specific development, regulatory, and

Duvyzat must be administered alongside corticosteroids and is not limited by the patient’s specific genetic mutation. The decision is applicable across all 27 EU member states, as well

The alliance leverages both companies’ experience in the field of biosimilars. By combining their resources, they aim to expedite the development process while expanding the product’s availability worldwide.

The designation is granted to iopofosine I 131 for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM), a subtype of lymphoplasmacytic lymphoma currently without a cure. WM remains

Lilly will get exclusive, global rights to research, develop, manufacture and commercialise these therapies with Camurus’ FluidCrystal technology. The agreement includes up to four drug compounds from Lilly.

Glepaglutide is intended for administering two times a week for SBS. The application is based on results from the pivotal Phase III clinical trial EASE-1, supported by interim

The company’s wholly owned subsidiary T-mab developed the drug. It is Mabwell’s first commercialised innovative drug, and the first introduced granulocyte colony-stimulating factor (G-CSF) developed with albumin long-acting